NCT05177770 - Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

April 5, 2023

Study Completion Date

April 5, 2023

Conditions

Metastatic Castration-resistant Prostate CancerProstate Cancer

Interventions

DRUG

SRF617

SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.

DRUG

etrumadenant

Etrumadenant is an A2aR and A2bR antagonist.

DRUG

zimberelimab

Zimberelimab is a fully human anti-PD-1 monoclonal antibody.

Trial Locations (9)

University of Miami - Sylvester Comprehensive Cancer Center, Miami

University of Michigan Health System, Ann Arbor

UT Southwestern, Dallas

START South Texas Accelerated Research Therapeutics, LLC, San Antonio

Comprehensive Cancer Centers of Nevada, Las Vegas

START Mountain Region, Utah Cancer Specialists, West Valley City

Fred Hutchinson Cancer Research Center, Seattle

BC Cancer - The Vancouver Centre, Vancouver

Université de Montreal - Centre de Recherche du Centre Hospitalier de L'Université de Montreal (CRCHUM), Montreal